Welcome to our dedicated page for Bioatla SEC filings (Ticker: BCAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real cost of BioAtla’s CAB antibody trials or the timing of its Beijing manufacturing agreements can take hours in dense SEC disclosures. BioAtla insider trading Form 4 transactions, complicated R&D footnotes, and patent-portfolio risks are scattered across multiple forms, leaving biotech investors piecing together critical data.
Stock Titan solves that problem. Our AI-powered summaries turn a 300-page BioAtla annual report 10-K simplified into key takeaways on cash burn, milestone payments, and CAB pipeline progress. Need the latest BioAtla quarterly earnings report 10-Q filing? We post it in real time and pair it with plain-English financial trendlines. Flash 8-K material events explained—such as interim efficacy results—arrive with context in minutes. And if you want to monitor BioAtla Form 4 insider transactions real-time, instant alerts show every executive stock move alongside historical patterns.
- understanding BioAtla SEC documents with AI—no biotech PhD required
- BioAtla executive stock transactions Form 4 and ownership shifts at a glance
- BioAtla proxy statement executive compensation decoded for dilution impact
- BioAtla earnings report filing analysis highlighting clinical spend versus cash runway
Whether you are screening for catalytic trial milestones, assessing patent strengths, or comparing quarter-on-quarter burn rates, our comprehensive dashboard has every filing type. Investors routinely ask, “How do I track BioAtla insider activity before data readouts?” or “Where can I see BioAtla SEC filings explained simply?”—the answer is right here. Stay ahead with AI context, real-time alerts, and a single view of every disclosure you need to make informed decisions on this innovative oncology company.
BioAtla, Inc. is asking stockholders to approve three proposals at a virtual special meeting on December 30, 2025. The first would approve the potential issuance of 20% or more of the common stock outstanding as of November 20, 2025 under Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement with Yorkville and Anson funds, allowing sales below Nasdaq’s minimum price beyond an Exchange Cap of 11,752,538 shares, which equals 19.99% of outstanding shares on that date. These arrangements include a $15.0 million equity purchase commitment and a $7.5 million pre-paid advance, partly already converted into 479,294 shares, plus a 243,428‑share commitment fee.
The second proposal would amend the charter to permit a reverse stock split of common stock at a ratio between 1‑for‑5 and 1‑for‑20 any time before June 30, 2026, at the board’s discretion. The goal is to raise the share price above Nasdaq’s $1.00 minimum bid and regain compliance after the stock traded below that level for more than 30 consecutive trading days, with a compliance deadline of February 2, 2026. The split would not change authorized share counts but would increase authorized, unissued shares and may affect liquidity, create odd lots, and potentially reduce market capitalization.
The third proposal would allow adjournment of the meeting for up to 30 days to solicit additional proxies if there are insufficient votes to pass the stock issuance or reverse stock split proposals. Failure to approve the stock issuance could force BioAtla to repay the pre-paid advances in cash, plus a 10% premium, which the company says could strain working capital and push it toward less favorable, potentially more dilutive financing alternatives.
BioAtla, Inc. (BCAB) is asking stockholders at a virtual special meeting to approve new financing flexibility and a reverse stock split to support its Nasdaq listing and capital needs.
Proposal One seeks approval under Nasdaq rules to issue 20% or more of the common stock outstanding as of November 20, 2025 under Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement with Yorkville and Anson funds. These arrangements include a $15.0 million standby equity facility and a $7.5 million pre-paid advance, and are currently capped at 11,752,538 shares, or 19.99% of outstanding stock. Approval would allow issuances above this cap but could result in material dilution.
Proposal Two would authorize a reverse stock split of the common stock in a range of 1-for-5 to 1-for-20 any time before June 30, 2026, with the exact ratio set later by the board. The main goal is to raise the share price to regain and maintain compliance with Nasdaq’s $1.00 minimum bid requirement after the company fell below that level for more than 30 consecutive trading days. Authorized share counts and par value would not change, and fractional shares would be cashed out.
Proposal Three would permit adjournment of the meeting to solicit more proxies if there are not enough votes to pass the stock issuance or reverse split proposals. The board unanimously recommends voting “FOR” all three proposals.
BioAtla, Inc. is registering up to $22.5 million of common stock plus 243,428 shares of common stock in connection with new financing arrangements. The company has already received $7.5 million of pre-paid advances from three investors, to be repaid in stock at prices tied to the market but not below $0.23 per share, with interest at 4% annually, rising to 18% on default. A separate standby equity purchase agreement lets BioAtla sell up to $15 million of additional shares to Yorkville over 36 months at 97% of market price, subject to a 4.99% ownership cap. Yorkville also receives the 243,428 commitment shares as a 2.00% fee. These structures provide flexible access to capital but could significantly dilute existing shareholders as shares are issued.
BioAtla remains a clinical-stage oncology company, reporting $8.3 million in cash as of September 30 2025, a new $2 million milestone payment from Context Therapeutics, and recent FDA alignment on a planned Phase 3 ozuriftamab vedotin trial.
BioAtla, Inc. entered into two financing arrangements that together provide access to up to $22.5 million in capital. The company agreed to a $7.5 million Pre-Paid Advance with Yorkville and Anson funds, for which it will receive approximately $7.13 million in gross proceeds as the advance is purchased at 95% of face value. The advance bears 4% annual interest, includes a 10% payment premium, matures 12 months after closing, and can be repaid in cash or through share issuances priced off the stock’s VWAP, subject to a floor price and Nasdaq rules.
Separately, BioAtla entered into a Standby Equity Purchase Agreement with Yorkville allowing it to sell up to $15.0 million of common stock over 36 months at 97% of the lowest VWAP over a three-day period for each draw. Yorkville received a $300,000 commitment fee paid in 243,428 shares at $1.2324 per share. Both arrangements are subject to a 4.99% ownership cap per investor and an overall 19.99% Nasdaq exchange cap on shares issuable unless stockholders approve issuances above that level.
BioAtla (BCAB) reported Q3 2025 results, highlighting a continued operating loss and liquidity pressure. The company recorded a quarterly net loss of
Operating expenses fell as programs wound down: R&D was
The balance sheet showed total liabilities of
BioAtla, Inc. (BCAB) furnished an 8-K announcing its Q3 2025 results and a clinical program update. The company reported that a press release covering the quarter ended September 30, 2025 has been provided as Exhibit 99.1.
The information in Item 2.02, including Exhibit 99.1, is being furnished, not filed, and will not be incorporated by reference into other filings. BioAtla’s common stock trades on The Nasdaq Capital Market under the symbol BCAB.
Jay M. Short, Chief Executive Officer, Director and reported 10% owner of BioAtla, Inc. (BCAB), filed a Form 4 disclosing a non-sale transaction on 08/31/2025. The filing shows 6,347 shares of Common Stock were withheld by the issuer at a price of $0.4555 to satisfy income tax and withholding obligations related to the vesting and net settlement of previously reported restricted stock units. After the withholding, the reporting person directly beneficially owned 2,243,678 shares. The Form 4 also reports indirect holdings: 793,547 shares held by spouse, two trusts with 258,727 shares each, 302,324 shares by Capia IP, LLC, and 50 shares by Himalaya Parent LLC, where the reporting person and spouse are managers. The filing was signed by an attorney-in-fact on 09/02/2025.
Christian Vasquez, an officer at BioAtla, Inc. (BCAB) who serves as Chief Accounting Officer, Corporate Controller and Secretary, reported a transaction dated 08/31/2025 in which 1,566 shares of common stock were withheld by the issuer at a price of $0.4555 per share to satisfy income tax and withholding obligations related to the vesting and net settlement of previously reported restricted stock units. The filing shows 283,564 shares beneficially owned following the transaction and is signed by Mr. Vasquez on 09/02/2025. The filer explains this is not a sale but a withholding to cover taxes on vested RSUs.
Eric Sievers, Chief Medical Officer of BioAtla, Inc. (BCAB), reported a withholding transaction tied to vested restricted stock units. On 08/31/2025, 2,729 shares were withheld at an effective price of $0.4555 to satisfy income tax and withholding obligations related to prior RSU vesting. After the withholding, the filing shows 364,574 shares beneficially owned by Sievers. The Form 4 was signed by an attorney-in-fact on 09/02/2025. The filing explicitly states this was a net settlement withholding, not an open-market sale.
FAQ
What is the current stock price of Bioatla (BCAB)?
What is the market cap of Bioatla (BCAB)?
